MedTech Business - August 4, 2021
Immunovia Inc to begin patient testing in the US
Immunovia, Inc has received final approval to begin patient testing for the IMMray PanCan-d test. The IMMray PanCan-d test is the first blood test on the market dedicated to the early detection of pancreatic cancer. “We are extremely pleased to have achieved this important milestone and to be able to launch the first non-invasive, highly […]
Uncategorized - April 28, 2021
On the threshold of commercial launch
Originating from research at Lund University, diagnostic company Immunovia is now extremely close to market launch and the first order for its early pancreatic cancer detection test. “We are tremendously excited about having the very first blood test ordered for analysis in the laboratory. Behind that order is a real, concerned patient, who needs to […]
Uncategorized - March 30, 2021
“This is a historical moment for Immunovia”
Immunovia has announced improved performance of its blood based IMMray PanCan-d test and positive results from a blinded clinical validation of the test in US. The company has announced the successful completion of the last development milestone of IMMray PanCan-d blood test designed for early detection of pancreatic cancer (PDAC). A blinded validation study data […]
Pharma Business - January 1, 2020
Q&A: Mats Grahn, CEO of Immunovia
Immunovia has achieved a major milestone; their commercial test model study recently showed that their blood test had a 95% accuracy for pancreatic cancer, and the company is now on track for commercialization of the IMMray PanCan-d commercial biomarker signature. What are the advantages with your test? “IMMray is an antibody-based technology that creates a snapshot […]
Collaboration - September 11, 2017
Immunovia collaborates with Lund University
Immunovia announces a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population. […]
New Market - June 29, 2017
Immunovia establishes US headquarters
The company has chosen Boston, Massachusetts USA, as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB. This new site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilities for commercialization, covering marketing, sales and customer support. A team have been […]
